Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

NCT00081315 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00081315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2003
Completion date
August 31, 2006
Enrollment
130
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

esophagitis, non-small cell lung carcinoma, pneumonitis